Self DNA perpetuates IPF lung fibroblast senescence in a cGAS-dependent manner.


Journal

Clinical science (London, England : 1979)
ISSN: 1470-8736
Titre abrégé: Clin Sci (Lond)
Pays: England
ID NLM: 7905731

Informations de publication

Date de publication:
17 04 2020
Historique:
received: 12 11 2019
revised: 25 03 2020
accepted: 26 03 2020
pubmed: 29 3 2020
medline: 21 7 2020
entrez: 29 3 2020
Statut: ppublish

Résumé

Senescence and mitochondrial stress are mutually reinforcing age-related processes that contribute to idiopathic pulmonary fibrosis (IPF); a lethal disease that manifests primarily in the elderly. Whilst evidence is accumulating that GMP-AMP synthase (cGAS) is crucial in perpetuating senescence by binding damaged DNA released into the cytosol, its role in IPF is not known. The present study examines the contributions of cGAS and self DNA to the senescence of lung fibroblasts from IPF patients (IPF-LFs) and age-matched controls (Ctrl-LFs). cGAS immunoreactivity was observed in regions of fibrosis associated with fibroblasts in lung tissue of IPF patients. Pharmacological inhibition of cGAS or its knockdown by silencing RNA (siRNA) diminished the escalation of IPF-LF senescence in culture over 7 days as measured by decreased p21 and p16 expression, histone 2AXγ phosphorylation and/or IL-6 production (P < 0.05, n = 5-8). The targeting of cGAS also attenuated etoposide-induced senescence in Ctrl-LFs (P < 0.05, n = 5-8). Levels of mitochondrial DNA (mDNA) detected by qPCR in the cytosol and medium of IPF-LFs or senescence-induced Ctrl-LFs were higher than Ctrl-LFs at baseline (P < 0.05, n = 5-7). The addition of DNAse I (100 U/ml) deaccelerated IPF-LF senescence (P < 0.05, n = 5), whereas ectopic mDNA or the induction of endogenous mDNA release augmented Ctrl-LF senescence in a cGAS-dependent manner (P < 0.05, n = 5). In conclusion, we provide evidence that cGAS reinforces lung fibroblast senescence involving damaged self DNA. The targeting of cGAS to supress senescent-like responses may have potential important therapeutic implications in the treatment of IPF.

Identifiants

pubmed: 32219338
pii: 222487
doi: 10.1042/CS20191160
doi:

Substances chimiques

CDKN1A protein, human 0
CDKN2A protein, human 0
Cyclin-Dependent Kinase Inhibitor p16 0
Cyclin-Dependent Kinase Inhibitor p21 0
DNA, Mitochondrial 0
DNA-Binding Proteins 0
Enzyme Inhibitors 0
H2AX protein, human 0
Histones 0
IL6 protein, human 0
Interleukin-6 0
Mitochondrial Proteins 0
TFAM protein, human 0
Transcription Factors 0
Nucleotidyltransferases EC 2.7.7.-
cGAS protein, human EC 2.7.7.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

889-905

Informations de copyright

© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Auteurs

Michael Schuliga (M)

School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.
Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.

Jane Read (J)

School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.
Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.

Kaj E C Blokland (KEC)

School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.
Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.
University of Groningen, University Medical Center Groningen, Department of Pathology and Medical Biology, Groningen Research Institute of Asthma and COPD and KOLFF Institute, Netherlands.
National Health and Medical Research Council Centre of Research Excellence in Pulmonary Fibrosis, Sydney, NSW, Australia.

David W Waters (DW)

School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.
Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.

Janette Burgess (J)

University of Groningen, University Medical Center Groningen, Department of Pathology and Medical Biology, Groningen Research Institute of Asthma and COPD and KOLFF Institute, Netherlands.

Cecilia Prêle (C)

Institute for Respiratory Health, University of Western Australia, Nedlands, WA, Australia.
Centre for Cell Therapy and Regenerative Medicine, School of Biomedical Sciences, University of Western Australia, Crawley, WA, Australia.
Ear Science Institute Australia, Subiaco, WA, Australia.

Steven E Mutsaers (SE)

Institute for Respiratory Health, University of Western Australia, Nedlands, WA, Australia.
Centre for Cell Therapy and Regenerative Medicine, School of Biomedical Sciences, University of Western Australia, Crawley, WA, Australia.

Jade Jaffar (J)

Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Prahran, Victoria, Australia.

Glen Westall (G)

Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Prahran, Victoria, Australia.

Andrew Reid (A)

Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.
School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.

Allen James (A)

John Hunter Hospital, Newcastle, NSW, Australia.

Christopher Grainge (C)

Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.
School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.
John Hunter Hospital, Newcastle, NSW, Australia.

Darryl A Knight (DA)

School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia.
Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.
Providence Health Care Research Institute, Vancouver, British Columbia, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH